| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10033916 | HBV | ENSG00000137869.16 | protein_coding | CYP19A1 | Yes | No | 1588 | P11511 Q05CU4 Q8IYG4 |
| TVIS30013901 | HIV | ENSG00000137869.16 | protein_coding | CYP19A1 | Yes | No | 1588 | P11511 Q05CU4 Q8IYG4 |
| TVIS30038294 | HIV | ENSG00000137869.16 | protein_coding | CYP19A1 | Yes | No | 1588 | P11511 Q05CU4 Q8IYG4 |
| TVIS20042103 | HPV | ENSG00000137869.16 | protein_coding | CYP19A1 | Yes | No | 1588 | P11511 Q05CU4 Q8IYG4 |
| TVIS20066497 | HPV | ENSG00000137869.16 | protein_coding | CYP19A1 | Yes | No | 1588 | P11511 Q05CU4 Q8IYG4 |
| TVIS20052205 | HPV | ENSG00000137869.16 | protein_coding | CYP19A1 | Yes | No | 1588 | P11511 Q05CU4 Q8IYG4 |
| TVIS44008818 | HTLV-1 | ENSG00000137869.16 | protein_coding | CYP19A1 | Yes | No | 1588 | P11511 Q05CU4 Q8IYG4 |
| TVIS44041779 | HTLV-1 | ENSG00000137869.16 | protein_coding | CYP19A1 | Yes | No | 1588 | P11511 Q05CU4 Q8IYG4 |
| TVIS44036552 | HTLV-1 | ENSG00000137869.16 | protein_coding | CYP19A1 | Yes | No | 1588 | P11511 Q05CU4 Q8IYG4 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CYP19A1 |
|---|---|
| DrugBank ID | DB00990 |
| Drug Name | Exemestane |
| Target ID | BE0002090 |
| UniProt ID | P11511 |
| Regulation Type | inhibitor |
| PubMed IDs | 11752352; 19930708; 19436613; 19337436; 19156139; 20360896; 18728707; 17020418; 15814851 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Koutras A, Giannopoulou E, Kritikou I, Antonacopoulou A, Evans TR, Papavassiliou AG, Kalofonos H: Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer. 2009 Nov 24;8:109. doi: 10.1186/1476-4598-8-109.@@Robinson A: A review of the use of exemestane in early breast cancer. Ther Clin Risk Manag. 2009 Feb;5(1):91-8. Epub 2009 Mar 26.@@Untch M, Jackisch C: Exemestane in early breast cancer: a review. Ther Clin Risk Manag. 2008 Dec;4(6):1295-304.@@Barnadas A, Gil M, Gonzalez S, Tusquets I, Munoz M, Arcusa A, Prieto L, Margeli-Vila M, Moreno A: Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer. 2009 Feb 10;100(3):442-9. doi: 10.1038/sj.bjc.6604868. Epub 2009 Jan 20.@@Abrial C, Durando X, Mouret-Reynier MA, Thivat E, Bayet-Robert M, Nayl B, Dubray P, Pomel C, Chollet P, Penault-Llorca F: Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials. Int J Gen Med. 2009 Jul 30;2:129-40.@@Nabholtz JM: Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manag. 2008 Feb;4(1):189-204.@@Brueggemeier RW: Update on the use of aromatase inhibitors in breast cancer. Expert Opin Pharmacother. 2006 Oct;7(14):1919-30.@@Brueggemeier RW, Hackett JC, Diaz-Cruz ES: Aromatase inhibitors in the treatment of breast cancer. Endocr Rev. 2005 May;26(3):331-45. Epub 2005 Apr 6. |
| Groups | Approved; Investigational |
| Direct Classification | Androgens and derivatives |
| SMILES | [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C |
| Pathways | |
| PharmGKB | PA449563 |
| ChEMBL | CHEMBL1200374 |
